Sponsor Deadline
Posted: 4/18/2022

NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)

This FOA will support exploratory/developmental research projects of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.

New and Early Stage Investigators should consider submitting to the NIBIB Trailblazer Award (https://grants.nih.gov/grants/guide/pa-files/PAR-16-390.html), which supports an enhanced, three-year R21 grant.


  • R21 Due Dates: Feb. 16, Jun. 16, Oct. 16
  • AIDS Due Dates: Jan. 7, May 7, Sep. 7

PAR-18-433 Expiration Date  New Date May 8, 2021 per issuance of NOT-EB-20-013. (Original Expiration Date: January 8, 2021 )

Amount Description

Application budgets may not exceed $275,000 direct costs over a maximum two-year funding period. No more than $200,000 in direct costs may be requested in any single year.

Funding Type